13-substituted methacycline compounds
View Patent ↗13-substituted methacycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 13-substituted methacycline compounds are described.
1. A 13-substituted methacycline compound of the formula:
wherein:
R 4 and R 4′ are each alkyl;
R 5 is hydrogen, hydroxyl, or a prodrug moiety;
R 6 is an alkyl or an aryl group, and pharmaceutically acceptable salts thereof.
2. The 13-substituted methacycline compound of claim 1 , wherein R 5 is hydroxyl.
3. The 13-substituted methacycline compound of claim 1 , wherein R 4 and R 4′ are each methyl.
4. The 13-substituted methacycline compound of claim 1 , wherein R 6 is alkyl.
5. The 13-substituted methacycline compound of claim 1 , wherein R 6 is aryl.
6. A method for treating a tetracycline responsive state in a mammal, comprising administering to said mammal a 13-substituted methacycline compound, such that said tetracycline responsive state is treated, wherein said 13-substituted methacycline compound is of the formula:
wherein:
R 4 and R 4′ are each alkyl;
R 5 is hydrogen, hydroxyl, or a prodrug moiety;
R 6 is an alkyl or an aryl group, and pharmaceutically acceptable salts thereof.
7. The method of claim 6 , wherein said tetracycline responsive state is a bacterial infection.
8. The method of claim 7 , wherein said bacterial infection is associated with E. coli.
9. The method of claim 7 , wherein said bacterial infection is associated with S. aureus.
10. The method of claim 7 , wherein said bacterial infection is associated with E. faecalis.
11. The method of claim 7 , wherein said bacterial infection is resistant to other tetracycline antibiotics.
12. The method of claim 6 , wherein said compound is administered with a pharmaceutically acceptable carrier.
13. A pharmaceutical composition comprising a therapeutically effective amount of a 13-substituted methacycline compound and a pharmaceutically acceptable carrier, wherein said 13-substituted methacycline compound is of the formula:
wherein:
R 4 and R 4′ are each alkyl;
R 5 is hydrogen, hydroxyl, or a prodrug moiety;
R 6 is an alkyl or an aryl group, and pharmaceutically acceptable salts thereof.